News | March 31, 2008

Registry Unveils “Real-World” Data on Novel Excel Stent

April 1, 2008 - “Real-world” use of a novel drug-eluting stent coated with a biodegradable polymer is associated with good clinical outcomes, according to one-year data from a large international registry.

Results of the CREATE study, which focused on the sirolimus-eluting Excel Stent were reported yesterday in a Late-Breaking Clinical Trials session at the SCAI Annual Scientific Sessions in Partnership with ACC i2 Summit (SCAI-ACCi2) in Chicago. SCAI-ACCi2 is a scientific meeting for practicing cardiovascular interventionalists sponsored by the Society for Cardiovascular Angiography and Interventions (SCAI) in partnership with the American College of Cardiology (ACC).

For the study, Yaling Han, M.D., Shenyang Northern Hospital, Shenyang, China, and colleagues recruited a total of 2,077 patients from 59 medical centers in four countries. All had stenting with the Excel stent, a novel device with a biodegradable polymer coating. Of these, 369 (17.8 percent) underwent primary stenting within 24 hours of having a heart attack.

After stenting, all patients were prescribed both clopidogrel and aspirin for six months to inhibit the action of platelets in the blood. Anti-platelet medications prevent the development of unwanted blood clots within the stent, or stent thrombosis, a serious complication that can cause heart attack or even death. On average, patients continued to take clopidogrel for 199 days.

Twelve-month follow-up data were available for 2,060 patients (99.2 percent). After 12 months, the overall rate of major cardiovascular complications was 2.77 percent, including cardiac death in 23 patients (1.12 percent), heart attack in 8 patients (0.39 percent), and repeat coronary procedure in 32 patients (1.55 percent). Death from any cause occurred in 34 patients (1.64 percent), including 11 noncardiac deaths. Overall, thrombotic complications occurred in 16 patients (0.78 percent), including six definite cases, five probable cases and five possible cases. Of these, three thrombotic complications (0.15 percent) occurred after discontinuation of clopidogrel.

The researchers concluded that the Excel stent is associated with a low incidence of cardiovascular complications, and that six months of dual-antiplatelet therapy appears to be feasible and safe.

For more information: www.scai-acci2.org

Related Content

The Medtronic Resolute Integrity drug-eluting stent is among the top three stents on the U.S. market. Outcomes for these stents are very similar, so the stents have largely become a commodity product purchased on price rather than clinical data. Stent advances and new stent technologies.

The Medtronic Resolute Integrity drug-eluting stent (DES) is among the top three stents on the U.S. market. Outcomes for these stents are very similar, so the stents have largely become a commodity product purchased on price rather than clinical data.

Feature | Stents | January 29, 2019 | Dave Fornell, Editor
There was a lot of hype and high hopes pinned on bioresorbable stent technologies as the way of the future two years
The Indian-made SMT SuperFlex stent. SMT has been developing stents and other interventional products designed to be a more affordable, home-grown option for the growing Indian market.

The Indian-made SMT SuperFlex stent. SMT has been developing stents and other interventional products designed to be a more affordable, home-grown option for the growing Indian market.

News | Stents | January 22, 2019
The rise cardiovascular disease has been instrumental in fueling the coronary stent market share in the past few year
The Biotronik Osiro is an ultra thin strut, sirolimus-eluting stent. #TCT2018

The Biotronik Osiro is an ultra thin strut, sirolimus-eluting stent.

News | Stents | October 04, 2018
October 4, 2018 – Investigators unveiled clinical data from the independent BIONYX and SORT OUT IX all-comers trials
FDA Approves Biotronik's PK Papyrus Stent for Coronary Perforations
Technology | Stents | September 27, 2018
September 27, 2018 — Biotronik recently announced U.S.
Videos | Stents | September 11, 2018
This is an animation showing how the dedicated bifurcation stent developed by Advanced Bifurcation Systems (ABS) is d
Elixir Medical Corporation Unveils Transformational DynamX Stent Featuring Adaptive Segments that Uncage the Stented Artery
News | Stents | January 25, 2018
January 25, 2018 – Elixir Medical Corporation, a leader in the development of breakthrough adaptive remodeling techno
The TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

The presentation of the ESC late-breaker TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

News | Stents | November 24, 2017
November 24, 2017 – During a late-breaking session at the European Society of Cardiology (ESC) 2017 meeting, presente
News | Stents | November 10, 2017
Cordis, a Cardinal Health company, recently unveiled a comprehensive interventional cardiology portfolio, which now...
OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

Feature | Stents | November 08, 2017
November 8, 2017 – New results from the HARMONEE Japan/U.S.
FDA Approves COBRA REDUCE Trial of 14-Day DAPT With CeloNova Stent
News | Stents | October 27, 2017
CeloNova BioSciences Inc. announced the U.S. Food and Drug Administration (FDA) approved expansion of CeloNova's...
Overlay Init